Ambulatory Pediatrics
Volume 2, Issue 2 , Pages 111-119 , March 2002

Ambulatory Use of Psychotropics by Employer-Insured Children and Adolescents in a National Managed Care Organization

  • Deborah Shatin, ACSW, PhD

      Affiliations

    • Corresponding Author InformationAddress correspondence to Deborah Shatin, ACSW, PhD, Center for Health Care Policy and Evaluation, UnitedHealth Group, 9900 Bren Rd E, MN008-W109, Minnetonka, MN 55343
    • ,
  • Carol R. Drinkard, MPH, PhD

      Affiliations

    • From the Center for Health Care Policy and Evaluation, UnitedHealth Group, Minnetonka, Minn

Received 20 October 2001 ,Accepted 5 December 2001.

REFERENCES 

  1. Bonati M . Epidemiologic evaluation of drug use in children . J Clin Pharmacol . 1994;34:300–305
  2. Zito JM , Safer DJ , Riddle MA , et al.   Prevalence variations in psychotropic treatment of children . J Child Adolesc Psychopharmacol . 1998;8:99–105
  3. Safer DJ , Zito JM , Fine EM . Increased methylphenidate usage for attention deficit disorder in the 1990s . Pediatrics . 1996;98:1084–1088
  4. Zito JM , Safer DJ , dosReis S , et al.   Methylphenidate patterns among Medicaid youths . Psychopharmacol Bull . 1997;33:143–147
  5. Zito JM , Safer DJ , dosReis S , et al.   Trends in the prescribing of psychotropic medications to preschoolers . JAMA . 2000;283:1025–1030
  6. Goldman LS , Genel M , Bezman RJ , Slanetz PJ . Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents . JAMA . 1998;279:1100–1107
  7. Zito JM , Safer DJ , dosReis S , et al.   Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder . Arch Pediatr Adolesc Med . 1999;153:1257–1263
  8. Rappley MD , Gardiner JC , Jetton JR , Houang RT . The use of methylphenidate in Michigan . Arch Pediatr Adolesc Med . 1995;149:675–679
  9. Safer DJ . Changing patterns of psychotropic medications prescribed by child psychiatrists in the 1990s . J Child Adolesc Psychopharmacol . 1997;7:267–274
  10. Sayal K . Debate is needed over who provides drug treatment in attention deficit hyperactivity disorder . BMJ . 1998;316:704
  11. Zametkin AJ , Ernst M . Problems in the management of attention-deficit-hyperactivity disorder . N Engl J Med . 1999;340:40–346
  12. In: AHCPR Technical Review Number 3: Diagnosis of Attention-Deficit/Hyperactivity Disorder . Rockville, Md: Agency for Health Care Policy and Research; 1999;p. 1–102 AHCPR publication 99-0050
  13. Wolraich ML , Hannah JN , Pinnock TY , et al.   Comparison of diagnostic criteria for attention-deficit hyperactivity disorder in a county-wide sample . J Am Acad Child Adolesc Psychiatry . 1996;35:319–324
  14. Brown RT , Freeman WS , Perrin JM , et al.   Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings . Pediatrics . 2001;107:E43
  15. Elia J , Ambrosini PJ , Rapoport JL . Treatment of attention-deficit hyperactivity disorder . N Engl J Med . 1999;340:780–788
  16. Wolraich ML , Hannah JN , Baumgaertel A , Feurer ID . Examination of DSM-IV criteria for attention deficit/hyperactivity disorder in a county-wide sample . J Dev Behav Pediatr . 1998;19:162–168
  17. American Academy of Pediatrics Committee on Quality Improvement, Subcommittee on Attention-Deficit/Hyperactivity Disorder. . Clinical practice guideline: Diagnosis and Evaluation of the Child With Attention-Deficit/Hyperactivity Disorder . Pediatrics . 2000;105:1158–1170
  18. Antonuccio DO , Danton WG , DeNelsky GY , et al.   Raising questions about antidepressants . Psychother Psychosom . 1999;68:3–14
  19. Summary, Evidence Report/Technology Assessment Number 7: Treatment of Depression—Newer Pharmacotherapies . Rockville, Md: Agency for Health Care Policy and Research; 1999; Available at: http://www.ahcpr.gov/clinic/deprsumm.htm
  20. Daly JM , Wilens M . The use of tricyclic antidepressants in children and adolescents . Child Adolesc Psychopharmacol . 1998;45:1123–1133
  21. Riddle MA , Labellarte MJ , Walkup JT . Pediatric psychopharmacology: problems and prospects [guest editorial] . J Child Adolesc Psychopharmacol . 1998;8:87–97
  22. Ten Eick AP , Nakamura H , Reed MD . Drug-drug interactions in pediatric psychopharmacology . Child Adolesc Psychopharmacol . 1998;45:1233–1264
  23. Labellarte MJ , Walkup JT , Riddle MA . The new antidepressants: selective serotonin reuptake inhibitors . Child Adolesc Psychopharmacol . 1998;45:1137–1155
  24. Emslie GJ , Walkup JT , Pliszka SR , Ernst M . Nontricyclic antidepressants: current trends in children and adolescents . J Am Acad Child Adolesc Psychiatry . 1999;38:517–528
  25. Jensen PS , Bhatara VS , Vitiello B , et al.   Psychoactive medication prescribing practices for US children: gaps between research and clinical practice . J Am Acad Child Adolesc Psychiatry . 1999;38:557–565
  26. Centers for Disease Control and Prevention. . Youth risk behavior surveillance—United States, 1999 . MMWR . 2000;49:1–94
  27. Olfson M , Klerman GL . Trends in the prescription of antidepressants by office-based psychiatrists . Am J Psychiatry . 1993;150:571–577
  28. Renaud J , Axelson D , Birmaher B . A risk-benefit assessment of pharmacotherapies for clinical depression in children and adolescents . Drug Safety . 1999;20:59–75
  29. Zarin DA . Clinical and treatment characteristics of children with attention-deficit/hyperactivity disorder in psychiatric practice . J Am Acad Child Adolesc Psychiatry . 1998;37:1262–1270

 Presented at the Pediatric Academic Societies Annual Meeting, Baltimore, Md, April 29, 2001.

PII: S1530-1567(05)60092-5

doi: 10.1367/1539-4409(2002)002<0111:AUOPBE>2.0.CO;2

Ambulatory Pediatrics
Volume 2, Issue 2 , Pages 111-119 , March 2002

Article Tools

* Image Usage & Resolution